NASDAQ:MGNX MacroGenics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MacroGenics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $24.69 -0.03 (-0.12 %) (As of 09/24/2020 12:00 AM ET) Add Compare Share Today's Range$23.81Now: $24.69▼$25.5050-Day Range$24.72MA: $27.27▼$31.6052-Week Range$4.04Now: $24.69▼$32.18Volume411,341 shsAverage Volume1.47 million shsMarket Capitalization$1.34 billionP/E RatioN/ADividend YieldN/ABeta2.63 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3; MGA012, an anti-PD-1 monoclonal antibody, which inhibits programmed cell death protein 1 (PD-1); MGD013, a monoclonal antibody that targets the immune checkpoints PD-1 and lymphocyte-activation gene 3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company is developing MGD009, a DART molecule that targets B7-H3 expressed on tumor cells and CD3; MGC018, an antibody drug conjugate, which targets solid tumors expressing B7-H3; and MGD007, a DART molecule, which targets glycoprotein A33 and CD3; and MGD014, a DART molecule that targets virus-infected cells. It has strategic collaborations with Incyte Corporation; Les Laboratoires Servier and Institut de Recherches Servier; and Zai Lab Limited. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.Read More Beat the Market (BTM) Rank™ 2.3 Analyst's Opinion Consensus RatingMacroGenics has received a consensus rating of Buy. The company's average rating score is 2.64, and is based on 11 buy ratings, 1 hold rating, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.83, MacroGenics has a forecasted upside of 24.9% from its current price of $24.69.Amount of Analyst CoverageMacroGenics has only been the subject of 4 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesMacroGenics has received 369 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMacroGenics has received 371 “underperform” votes. (Add your “underperform” vote.)Community SentimentMacroGenics has received 50.14% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about MacroGenics and other stocks. Vote “Outperform” if you believe MGNX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MGNX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMacroGenics does not currently pay a dividend.Dividend GrowthMacroGenics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MacroGenics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,888,971.00 in company stock.Percentage Held by InsidersOnly 9.00% of the stock of MacroGenics is held by insiders.Percentage Held by Institutions95.03% of the stock of MacroGenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MacroGenics are expected to grow in the coming year, from ($3.47) to ($2.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MacroGenics is -7.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MacroGenics is -7.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMacroGenics has a P/B Ratio of 5.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.29 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MGNX Previous Symbol CUSIPN/A CIK1125345 Webwww.macrogenics.com Phone301-251-5172Debt Debt-to-Equity RatioN/A Current Ratio5.67 Quick Ratio5.67Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$64.19 million Price / Sales20.82 Cash FlowN/A Price / Cash FlowN/A Book Value$4.71 per share Price / Book5.24Profitability EPS (Most Recent Fiscal Year)($3.16) Net Income$-151,810,000.00 Net Margins-214.06% Return on Equity-72.15% Return on Assets-53.05%Miscellaneous Employees364 Outstanding Shares54,117,000Market Cap$1.34 billion Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $24.69 -0.03 (-0.12 %) (As of 09/24/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MGNX News and Ratings via Email Sign-up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. MacroGenics (NASDAQ:MGNX) Frequently Asked Questions How has MacroGenics' stock price been impacted by Coronavirus? MacroGenics' stock was trading at $6.49 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MGNX shares have increased by 280.4% and is now trading at $24.69. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of MacroGenics? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 2 sell ratings, 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MacroGenics. When is MacroGenics' next earnings date? MacroGenics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for MacroGenics. How were MacroGenics' earnings last quarter? MacroGenics Inc (NASDAQ:MGNX) announced its earnings results on Thursday, July, 30th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.92) by $0.02. The biopharmaceutical company earned $20.26 million during the quarter, compared to analysts' expectations of $14.19 million. MacroGenics had a negative return on equity of 72.15% and a negative net margin of 214.06%. View MacroGenics' earnings history. What price target have analysts set for MGNX? 14 Wall Street analysts have issued 12-month target prices for MacroGenics' stock. Their forecasts range from $8.00 to $50.00. On average, they anticipate MacroGenics' share price to reach $30.83 in the next twelve months. This suggests a possible upside of 24.9% from the stock's current price. View analysts' price targets for MacroGenics. Who are some of MacroGenics' key competitors? Some companies that are related to MacroGenics include Emergent Biosolutions (EBS), Blueprint Medicines (BPMC), Ultragenyx Pharmaceutical (RARE), BridgeBio Pharma (BBIO), Arrowhead Pharmaceuticals (ARWR), Zai Lab (ZLAB), United Therapeutics (UTHR), HUTCHISON CHINA/S (HCM), Arena Pharmaceuticals (ARNA), MorphoSys (MOR), Evotec (EVTCY), FibroGen (FGEN), Allakos (ALLK), Legend Biotech (LEGN) and Biohaven Pharmaceutical (BHVN). View all competitors. What other stocks do shareholders of MacroGenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), NVIDIA (NVDA), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Intra-Cellular Therapies (ITCI), Micron Technology (MU), TG Therapeutics (TGTX) and Bausch Health Companies (BHC). Who are MacroGenics' key executives? MacroGenics' management team includes the following people: Dr. Scott Koenig, CEO, Pres & Director (Age 67)Mr. James Karrels, Sr. VP, CFO & Sec. (Age 52)Dr. Ezio Bonvini, Sr. VP of Research & Chief Scientific Officer (Age 65)Mr. Eric Blasius Risser, Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer (Age 46)Dr. Jon M. Wigginton, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 57) What is MacroGenics' stock symbol? MacroGenics trades on the NASDAQ under the ticker symbol "MGNX." Who are MacroGenics' major shareholders? MacroGenics' stock is owned by a number of retail and institutional investors. Top institutional investors include Bellevue Group AG (9.24%), Vanguard Group Inc. (6.06%), Wasatch Advisors Inc. (4.27%), Great Point Partners LLC (2.77%), Point72 Asset Management L.P. (2.51%) and Perceptive Advisors LLC (2.38%). Company insiders that own MacroGenics stock include Eric Blasius Risser, Ezio Bonvini, Jeffrey Stuart Peters, Kenneth Galbraith, Matthew K Fust and Thomas Spitznagel. View institutional ownership trends for MacroGenics. Which major investors are selling MacroGenics stock? MGNX stock was sold by a variety of institutional investors in the last quarter, including Bellevue Group AG, Rhenman & Partners Asset Management AB, Wasatch Advisors Inc., Candriam Luxembourg S.C.A., Pinnacle Associates Ltd., Nuveen Asset Management LLC, Man Group plc, and FMR LLC. Company insiders that have sold MacroGenics company stock in the last year include Eric Blasius Risser, Ezio Bonvini, Kenneth Galbraith, and Thomas Spitznagel. View insider buying and selling activity for MacroGenics. Which major investors are buying MacroGenics stock? MGNX stock was purchased by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Perceptive Advisors LLC, RTW Investments LP, Point72 Asset Management L.P., Goldman Sachs Group Inc., Assenagon Asset Management S.A., Macquarie Group Ltd., and Opaleye Management Inc.. View insider buying and selling activity for MacroGenics. How do I buy shares of MacroGenics? Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is MacroGenics' stock price today? One share of MGNX stock can currently be purchased for approximately $24.69. How big of a company is MacroGenics? MacroGenics has a market capitalization of $1.34 billion and generates $64.19 million in revenue each year. The biopharmaceutical company earns $-151,810,000.00 in net income (profit) each year or ($3.16) on an earnings per share basis. MacroGenics employs 364 workers across the globe. What is MacroGenics' official website? The official website for MacroGenics is www.macrogenics.com. How can I contact MacroGenics? MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172. This page was last updated on 9/25/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
